{"groups":[{"description":"80mg once daily tablet","id":"FG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"FG001","title":"Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"111"},{"groupId":"FG001","numSubjects":"52"}],"type":"Ongoing study at data cut-off"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"73"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"32"},{"groupId":"FG001","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"111"},{"groupId":"FG001","numSubjects":"52"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Patients assigned to osimertinib may continue to receive osimertinib if, in the opinion of their treating physician, they are continuing to derive clinical benefit. Patients receiving placebo may receive open-label osimertinib, in accordance with local clinical practice and the judgement of their treating physician. For all patients, post-progression treatment with AZ-supply osimertinib may continue as long as the treating physician considers the patient to be deriving clinical benefit"}